Dr. Reddy’s Laboratories (NYSE: RDY) to appoint Deloitte as new auditor

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited reported a change in auditors driven by mandatory auditor rotation under the Indian Companies Act, 2013. Deloitte Haskins & Sells LLP has been recommended as the new statutory auditor for 5 consecutive years, from the conclusion of the 42nd Annual General Meeting to the 47th, subject to shareholder approval. To align global reporting, the Board also approved Deloitte as the company’s Independent Registered Public Accounting Firm for its Form 20-F audits and Form 6-K interim reviews. Ernst & Young Associates LLP served in this role through the audit for the year ended March 31, 2026 and the interim review for the three months ended June 30, 2026. The company is using this report and EY’s accompanying letter to meet Item 16F(a) disclosure requirements and to incorporate the change into certain Form S-8 registration statements.

Key Figures

Auditor term length: 5 consecutive years Prior audit year by EY: Year ended March 31, 2026 Interim review by EY: Three months ended June 30, 2026 +2 more

5 metrics

Auditor term length 5 consecutive years From the conclusion of the 42nd AGM until the conclusion of the 47th AGM

Prior audit year by EY Year ended March 31, 2026 EY served as Independent Registered Public Accounting Firm through this audit

Interim review by EY Three months ended June 30, 2026 EY completed the interim review for this period

Form 20-F year-end for Item 16F(a) March 31, 2027 Year ending used for the company’s Item 16F(a) disclosure obligations

Form S-8 file numbers 333-101013, 333-141072, 333-227193 Registration statements into which this report is incorporated by reference

Key Terms

statutory auditors, Independent Registered Public Accounting Firm, Item 16F(a), Form S-8

4 terms

statutory auditors regulatory

"audited annually by auditors ... sometimes referred to as “statutory auditors”"

Statutory auditors are independent, legally required professionals who examine a company's financial statements and records to confirm they are accurate and comply with law. Think of them as an impartial inspector or referee who checks the bookkeeping and internal controls; their reports give investors confidence that reported profits, losses and risks are reliable and help detect errors, fraud or accounting problems that could affect a company’s value.

Independent Registered Public Accounting Firm regulatory

"approved the appointment of Deloitte as the Independent Registered Public Accounting Firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Item 16F(a) regulatory

"to satisfy its reporting obligations under Item 16F(a) of its Form 20-F"

Form S-8 regulatory

"incorporated by reference into the Company’s registration statements on Form S-8"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/23/2026 - 12:18 PM Accepted by SEC EDGAR 07/23/2026 - 12:17 PM Learn about SEC filing dates

FAQ

What auditor change did Dr. Reddy’s (RDY) disclose in this Form 6-K?

Dr. Reddy’s (RDY) disclosed that Deloitte Haskins & Sells LLP has been recommended as its new statutory auditor and Independent Registered Public Accounting Firm, replacing Ernst & Young Associates LLP after the March 31, 2026 audit and June 30, 2026 interim review.

Why is Dr. Reddy’s (RDY) changing from EY to Deloitte as auditor?

The change from EY to Deloitte is to comply with Section 139 of the Indian Companies Act, 2013, which requires rotation of statutory auditors after they complete the maximum permitted term for Indian companies such as Dr. Reddy’s.

How long is Deloitte’s proposed audit term for Dr. Reddy’s (RDY)?

Deloitte is proposed to serve for 5 consecutive years, from the conclusion of Dr. Reddy’s 42nd Annual General Meeting until the conclusion of the 47th Annual General Meeting, subject to approval by the company’s shareholders.

What role did EY play for Dr. Reddy’s (RDY) before this auditor change?

Ernst & Young Associates LLP acted as Dr. Reddy’s Independent Registered Public Accounting Firm through the audit for the year ended March 31, 2026 and the interim review for the three months ended June 30, 2026.

How is this auditor change used in Dr. Reddy’s (RDY) SEC reporting?

Dr. Reddy’s will use this report and EY’s letter to satisfy Item 16F(a) requirements for its Form 20-F for the year ending March 31, 2027 and incorporate them by reference into certain Form S-8 registration statements.

Does Deloitte’s appointment for Dr. Reddy’s (RDY) cover U.S. SEC filings?

Yes. Deloitte is approved as Dr. Reddy’s Independent Registered Public Accounting Firm for auditing financial statements included in the company’s Form 20-F and reviewing interim financial statements filed with the U.S. SEC on Form 6-K.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                                Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Change in Auditors

Dr. Reddy’s Laboratories Limited (the “Company”) is furnishing this current report on Form 6-K to report a change in its auditors.

Under the Indian Companies Act, 2013 (the “Companies Act’’) and the rules made thereunder, an Indian company such as the Company is required to have their financial statements audited annually by auditors for purposes of ensuring compliance with Indian Accounting Standards and certain other Indian laws (sometimes referred to as “statutory auditors”). Under Section 139 of the Companies Act, Indian companies must rotate their current statutory auditors once the auditors have completed the maximum term permitted under the said regulation. Therefore, the Company's Audit Committee and the Board on May 12, 2026, recommended the appointment of Deloitte Haskins & Sells, LLP (“Deloitte”) as the new statutory auditors of the Company. Deloitte will hold office for a period of 5 (five) consecutive years from the conclusion of the 42^nd Annual General Meeting of the Company until the conclusion of the 47^th Annual General Meeting, subject to the approval of shareholders of the Company.

To align with the above, and based upon the recommendation of the Audit Committee, the Board of Directors of the Company in its meeting held on July 22, 2026, approved the appointment of Deloitte as the Independent Registered Public Accounting Firm of the Company for purposes of auditing the financial statements of the Company to be included in the Company’s Annual Report on Form 20-F and reviewing the interim financial statements to be filed with the U.S. Securities and Exchange Commission on Form 6-K. Ernst & Young Associates LLP (“EY”) was the Company's Independent Registered Public Accounting Firm through the completion of the audit for the year ended March 31, 2026 and the interim review for the three months period  ended June 30, 2026.

In addition, in accordance with disclosure requirements under SEC regulations, the following may be noted:

a) The audit reports of EY on the consolidated financial statements of the Company as of and for the fiscal years ended March 31, 2026 and 2025 did not contain any adverse opinion or disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles.

b) During the fiscal years ended March 31, 2026 and 2025 and during the period from April 1, 2026 through the date hereof, there were (i) no “disagreements” with EY, as such term is used in Item 16F(a)(1)(iv) of Form 20-F (and the related instructions thereto), and defined in Instruction 4 to Item 16F over any matters with EY on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures that, if not resolved to EY’s satisfaction, would have caused EY to make reference to the subject matter of the disagreement(s) in connection with its reports, and (ii) no “reportable events,” as the term is described in Item 16F(a)(1)(v) of Form 20-F.

c) During the fiscal years ended March 31, 2026 and 2025 and during the period from April 1, 2026 through the date hereof, neither the Company nor anyone acting on the Company’s behalf consulted Deloitte regarding either:

o the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to the consolidated financial statements of the Company; or

o any matter that was the subject of a disagreement as defined in Item 16F(a)(l)(iv) of Form 20-F and the related instructions or a "reportable event" as described in Item 16F(a)(l)(v) of Form 20-F.

The Company provided EY with a copy of this foregoing disclosure and requested that EY furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether EY agrees with the above statements, and, if not, stating the respects in which it does not agree. A copy of EY’s letter is furnished as Exhibit 15.3 to this Form 6-K.The Company intends to use this Form 6-K and the accompanying exhibit to satisfy its reporting obligations under Item 16F(a) of its Form 20-F for the year ending March 31, 2027 to the extent provided in and permitted by Paragraph 2 of the Instructions to Item 16F of Form 20-F and plans to incorporate this report on Form 6-K, including Exhibit 15.3, by reference to its Form 20-F to the extent necessary to satisfy such reporting obligations. The information contained in this report on Form 6-K is hereby incorporated by reference into the Company’s registration statements on Form S-8 (Nos. 333-101013, 333-141072 and 333-227193) that were filed with the U.S. Securities and Exchange Commission.

2

EXHIBITS

Exhibit Number		Description of Exhibits
15.3		Letter from Ernst & Young Associates LLP to the U.S. Securities and Exchange Commission dated July 23, 2026

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: July 23, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

4

Filing Exhibits & Attachments

1 document

Other Documents

• EX-15.3 EXHIBIT 15.3 7.3 KB